<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36982194</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>07</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Towards a Better Understanding of the Complexities of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5124</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24065124</ELocationID><Abstract><AbstractText>Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex condition arising in susceptible people, predominantly following viral infection, but also other stressful events. The susceptibility factors discussed here are both genetic and environmental although not well understood. While the dysfunctional physiology in ME/CFS is becoming clearer, understanding has been hampered by different combinations of symptoms in each affected person. A common core set of mainly neurological symptoms forms the modern clinical case definition, in the absence of an accessible molecular diagnostic test. This landscape has prompted interest in whether ME/CFS patients can be classified into a particular phenotype/subtype that might assist better management of their illness and suggest preferred therapeutic options. Currently, the same promising drugs, nutraceuticals, or behavioral therapies available can be beneficial, have no effect, or be detrimental to each individual patient. We have shown that individuals with the same disease profile exhibit unique molecular changes and physiological responses to stress, exercise and even vaccination. Key features of ME/CFS discussed here are the possible mechanisms determining the shift of an immune/inflammatory response from transient to chronic in ME/CFS, and how the brain and CNS manifests the neurological symptoms, likely with activation of its specific immune system and resulting neuroinflammation. The many cases of the post viral ME/CFS-like condition, Long COVID, following SARS-CoV-2 infection, and the intense research interest and investment in understanding this condition, provide exciting opportunities for the development of new therapeutics that will benefit ME/CFS patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tate</LastName><ForeName>Warren P</ForeName><Initials>WP</Initials><Identifier Source="ORCID">0000-0002-6971-7734</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, School of Biomedical Sciences, Division of Health Sciences, University of Otago, Dunedin 9054, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Max O M</ForeName><Initials>MOM</Initials><Identifier Source="ORCID">0009-0002-0173-5482</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, School of Biomedical Sciences, Division of Health Sciences, University of Otago, Dunedin 9054, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peppercorn</LastName><ForeName>Katie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, School of Biomedical Sciences, Division of Health Sciences, University of Otago, Dunedin 9054, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blair</LastName><ForeName>Anna L H</ForeName><Initials>ALH</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, School of Biomedical Sciences, Division of Health Sciences, University of Otago, Dunedin 9054, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edgar</LastName><ForeName>Christina D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, School of Biomedical Sciences, Division of Health Sciences, University of Otago, Dunedin 9054, New Zealand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>no grant number</GrantID><Agency>ANZMES -NZA ME/CFS natiuonal disease advisory association</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015673" MajorTopicYN="Y">Fatigue Syndrome, Chronic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015984" MajorTopicYN="N">Causality</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">ME/CFS</Keyword><Keyword MajorTopicYN="N">disease models</Keyword><Keyword MajorTopicYN="N">disease subtype/phenotype</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">susceptibility</Keyword><Keyword MajorTopicYN="N">systemic inflammation</Keyword><Keyword MajorTopicYN="N">therapeutics</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>1</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36982194</ArticleId><ArticleId IdType="pmc">PMC10048882</ArticleId><ArticleId IdType="doi">10.3390/ijms24065124</ArticleId><ArticleId IdType="pii">ijms24065124</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Walker M.O.M., Hall K.H., Peppercorn K., Tate W.P. The significance of oxidative stress in the pathophysiology of Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Med. Res. Arch. 2022;10:1&#x2013;22. doi: 10.18103/mra.v10i9.3050.</Citation><ArticleIdList><ArticleId IdType="doi">10.18103/mra.v10i9.3050</ArticleId></ArticleIdList></Reference><Reference><Citation>Lidbury B.A., Fisher P.R. Biomedical Insights that Inform the Diagnosis of ME/CFS. Diagnostics. 2020;10:92. doi: 10.3390/diagnostics10020092.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics10020092</ArticleId><ArticleId IdType="pmc">PMC7168303</ArticleId><ArticleId IdType="pubmed">32046358</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff A.L., Lipkin W.I. Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome. Trends Mol. Med. 2021;27:895&#x2013;906. doi: 10.1016/j.molmed.2021.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2021.06.002</ArticleId><ArticleId IdType="pmc">PMC8180841</ArticleId><ArticleId IdType="pubmed">34175230</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>White P.D., Thomas J.M., Amess J., Crawford D.H., Grover S.A., Kangro H.O., Clare A.W. Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever. Br. J. Psychiatry. 1998;173:475&#x2013;481. doi: 10.1192/bjp.173.6.475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.173.6.475</ArticleId><ArticleId IdType="pubmed">9926075</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney L.L., Routen A., Gillies C., Ekezie W., Welford A., Zhang A., Karamchandani U., Simms-Williams N., Cassambai S., Ardavani A., et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. eClinicalMedicine. 2023;55:101762. doi: 10.1016/j.eclinm.2022.101762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101762</ArticleId><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis R.H., Santillana M., Ognyanova K., Safarpour A., Lunz Trujillo K., Simonson M.D., Green J., Quintana A., Druckman J., Baum M.A., et al. Prevalence and Correlates of Long COVID Symptoms Among US Adults. JAMA Netw. Open. 2022;5:e2238804. doi: 10.1001/jamanetworkopen.2022.38804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.38804</ArticleId><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugiyama A., Miwata K., Kitahara Y., Okimoto M., Abe K., Bunthen E., Ouoba S., Akita T., Tanimine N., Ohdan H., et al. Long COVID occurrence in COVID-19 survivors. Sci. Rep. 2022;12:6039. doi: 10.1038/s41598-022-10051-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-10051-z</ArticleId><ArticleId IdType="pmc">PMC8996498</ArticleId><ArticleId IdType="pubmed">35411017</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., Penfold R.S., Merino J., Sudre C.H., Molteni E., Berry S., Canas L.S., Graham M.S., Klaser K., Modat M., et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: A prospective, community-based, nested, case-control study. Lancet Infect. Dis. 2022;22:43&#x2013;55. doi: 10.1016/S1473-3099(21)00460-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00460-6</ArticleId><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson C. Counterpoint: Yes, Long COVID is Helping Chronic Fatigue Syndrome (ME/CFS)&#x2026; Health Rising Blog. 2022.  [(accessed on 22 January 2023)].  Available online:  https://www.healthrising.org/blog/2022/10/25/counterpoint-long-covid-chronic-fatigue-syndrome/</Citation></Reference><Reference><Citation>Friedman K.J., Murovska M., Pheby D.F.H., Zalewski P. Our Evolving Understanding of ME/CFS. Medicina. 2021;57:200. doi: 10.3390/medicina57030200.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57030200</ArticleId><ArticleId IdType="pmc">PMC7996879</ArticleId><ArticleId IdType="pubmed">33652622</ArticleId></ArticleIdList></Reference><Reference><Citation>Various  Topical Collection &#x201c;Why Some Patients Never Fully Recover: Post Active Phase of Infection Syndromes (PAPIS)&#x201d;.  [(accessed on 22 January 2023)];Healthcare. 2023  Available online:  https://www.mdpi.com/journal/healthcare/topical_collections/PAPIS.</Citation></Reference><Reference><Citation>Tate W., Walker M., Sweetman E., Helliwell A., Peppercorn K., Edgar C., Blair A., Chatterjee A. Molecular Mechanisms of Neuroinflammation in ME/CFS and Long COVID to Sustain Disease and Promote Relapses. Front. Neurol. 2022;13:877772. doi: 10.3389/fneur.2022.877772.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2022.877772</ArticleId><ArticleId IdType="pmc">PMC9174654</ArticleId><ArticleId IdType="pubmed">35693009</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair A. A Quantitative Investigation into the Personal and Family Health Histories of Long COVID and ME/CFS Patients: Identifying Susceptibility Factors and Support Needs. University of Technology Sydney; Ultimo, NSW, Australia: 2022.</Citation></Reference><Reference><Citation>Wong T.L., Weitzer D.J. Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)&#x2014;A Systemic Review and Comparison of Clinical Presentation and Symptomatology. Medicina. 2021;57:418. doi: 10.3390/medicina57050418.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57050418</ArticleId><ArticleId IdType="pmc">PMC8145228</ArticleId><ArticleId IdType="pubmed">33925784</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M., Manoharan L., Elkheir N., Cheng V., Dagens A., Hastie C., O&#x2019;Hara M., Suett J., Dahmash D., Bugaeva P., et al. Characterising long COVID: A living systematic review. BMJ Glob. Health. 2021;6:e005427. doi: 10.1136/bmjgh-2021-005427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long COVID&#x2014;Mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt J., Blease C., Geraghty K.J. Long Covid at the crossroads: Comparisons and lessons from the treatment of patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) J. Health Psychol. 2022;27:3106&#x2013;3120. doi: 10.1177/13591053221084494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/13591053221084494</ArticleId><ArticleId IdType="pubmed">35341334</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukocheva O.A., Maksoud R., Beeraka N.M., Madhunapantula S.V., Sinelnikov M., Nikolenko V.N., Neganova M.E., Klochkov S.G., Amjad Kamal M., Staines D.R., et al. Analysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome. J. Adv. Res. 2022;40:179&#x2013;196. doi: 10.1016/j.jare.2021.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jare.2021.11.013</ArticleId><ArticleId IdType="pmc">PMC8619886</ArticleId><ArticleId IdType="pubmed">36100326</ArticleId></ArticleIdList></Reference><Reference><Citation>Gherardi R.K., Cr&#xe9;peaux G., Authier F.J. Myalgia and chronic fatigue syndrome following immunization: Macrophagic myofasciitis and animal studies support linkage to aluminum adjuvant persistency and diffusion in the immune system. Autoimmun. Rev. 2019;18:691&#x2013;705. doi: 10.1016/j.autrev.2019.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2019.05.006</ArticleId><ArticleId IdType="pubmed">31059838</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron B., Flamand L., Juwana H., Middeldorp J., Naing Z., Rawlinson W., Ablashi D., Lloyd A. Serological and virological investigation of the role of the herpesviruses EBV, CMV and HHV-6 in post-infective fatigue syndrome. J. Med. Virol. 2010;82:1684&#x2013;1688. doi: 10.1002/jmv.21873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.21873</ArticleId><ArticleId IdType="pubmed">20827765</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatcher S., House A. Life events, difficulties and dilemmas in the onset of chronic fatigue syndrome: A case-control study. Psychol. Med. 2003;33:1185&#x2013;1192. doi: 10.1017/S0033291703008274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291703008274</ArticleId><ArticleId IdType="pubmed">14580073</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlauch K.A., Khaiboullina S.F., De Meirleir K.L., Rawat S., Petereit J., Rizvanov A.A., Blatt N., Mijatovic T., Kulick D., Palot&#xe1;s A., et al. Genome-wide association analysis identifies genetic variations in subjects with myalgic encephalomyelitis/chronic fatigue syndrome. Transl. Psychiatry. 2016;6:e730. doi: 10.1038/tp.2015.208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/tp.2015.208</ArticleId><ArticleId IdType="pmc">PMC4872418</ArticleId><ArticleId IdType="pubmed">26859813</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith A.K., Fang H., Whistler T., Unger E.R., Rajeevan M.S. Convergent genomic studies identify association of GRIK2 and NPAS2 with chronic fatigue syndrome. Neuropsychobiology. 2011;64:183&#x2013;194. doi: 10.1159/000326692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000326692</ArticleId><ArticleId IdType="pmc">PMC3701888</ArticleId><ArticleId IdType="pubmed">21912186</ArticleId></ArticleIdList></Reference><Reference><Citation>Dibble J.J., McGrath S.J., Ponting C.P. Genetic risk factors of ME/CFS: A critical review. Hum. Mol. Genet. 2020;29:R117&#x2013;R124. doi: 10.1093/hmg/ddaa169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddaa169</ArticleId><ArticleId IdType="pmc">PMC7530519</ArticleId><ArticleId IdType="pubmed">32744306</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajdarevic R., Lande A., Mehlsen J., Rydland A., Sosa D.D., Strand E.B., Mella O., Pociot F., Fluge &#xd8;., Lie B.A., et al. Genetic association study in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) identifies several potential risk loci. Brain Behav. Immun. 2022;102:362&#x2013;369. doi: 10.1016/j.bbi.2022.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2022.03.010</ArticleId><ArticleId IdType="pubmed">35318112</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S., Taylor K., Kozubek J., Sardell J., Gardner S. Genetic risk factors for ME/CFS identified using combinatorial analysis. J. Transl. Med. 2022;20:598. doi: 10.1186/s12967-022-03815-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03815-8</ArticleId><ArticleId IdType="pmc">PMC9749644</ArticleId><ArticleId IdType="pubmed">36517845</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers B.M., Jain A.K., De Meirleir K.L., Peterson D.L., Klimas N.G., Lerner A.M., Bested A.C., Flor-Henry P., Joshi P., Powles A.C.P., et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. J. Chronic Fatigue Syndr. 2003;11:7&#x2013;115. doi: 10.1300/J092v11n01_02.</Citation><ArticleIdList><ArticleId IdType="doi">10.1300/J092v11n01_02</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers B.M., van de Sande M.I., De Meirleir K.L., Klimas N.G., Broderick G., Mitchell T., Staines D., Powles A.C.P., Speight N., Vallings R., et al. Myalgic encephalomyelitis: International Consensus Criteria. J. Intern. Med. 2011;270:327&#x2013;338. doi: 10.1111/j.1365-2796.2011.02428.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2011.02428.x</ArticleId><ArticleId IdType="pmc">PMC3427890</ArticleId><ArticleId IdType="pubmed">21777306</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay A., Tate W.P. A compromised paraventricular nucleus within a dysfunctional hypothalamus: A novel neuroinflammatory paradigm for ME/CFS. Int. J. Immunopathol. Pharmacol. 2018;32:2342. doi: 10.1177/2058738418812342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2058738418812342</ArticleId></ArticleIdList></Reference><Reference><Citation>Murga I., Aranburu L., Gargiulo P.A., G&#xf3;mez Esteban J.C., Lafuente J.V. Clinical Heterogeneity in ME/CFS. A Way to Understand Long-COVID19 Fatigue. Front. Psychiatry. 2021;12:735784. doi: 10.3389/fpsyt.2021.735784.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2021.735784</ArticleId><ArticleId IdType="pmc">PMC8542754</ArticleId><ArticleId IdType="pubmed">34707521</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Zang C., Xu Z., Zhang Y., Xu J., Bian J., Morozyuk D., Khullar D., Zhang Y., Nordvig A.S., et al. Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat. Med. 2023;29:226&#x2013;235. doi: 10.1038/s41591-022-02116-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02116-3</ArticleId><ArticleId IdType="pmc">PMC9873564</ArticleId><ArticleId IdType="pubmed">36456834</ArticleId></ArticleIdList></Reference><Reference><Citation>Schacterle R.S., Komaroff A.L. A comparison of pregnancies that occur before and after the onset of chronic fatigue syndrome. Arch. Intern. Med. 2004;164:401&#x2013;404. doi: 10.1001/archinte.164.4.401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.164.4.401</ArticleId><ArticleId IdType="pubmed">14980991</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruun K.D., Amris K., Vaegter H.B., Blichfeldt-Eckhardt M.R., Holsgaard-Larsen A., Christensen R., Toft P. Low-dose naltrexone for the treatment of fibromyalgia: Protocol for a double-blind, randomized, placebo-controlled trial. Trials. 2021;22:804. doi: 10.1186/s13063-021-05776-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-021-05776-7</ArticleId><ArticleId IdType="pmc">PMC8591911</ArticleId><ArticleId IdType="pubmed">34781989</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosby L.D., Kalanidhi S., Bonilla A., Subramanian A., Ballon J.S., Bonilla H. Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A retrospective study of 101 patients treated with a low dose of Aripiprazole. J. Transl. Med. 2021;19:50. doi: 10.1186/s12967-021-02721-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-021-02721-9</ArticleId><ArticleId IdType="pmc">PMC7860172</ArticleId><ArticleId IdType="pubmed">33536023</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Mitoma F., Turgonyi E., Kumar A., Lim W., Larocque L., Hyde B.M. Clinical Improvement in Chronic Fatigue Syndrome Is Associated with Enhanced Natural Killer Cell-Mediated Cytotoxicity: The Results of a Pilot Study with Isoprinosine&#xae;. J. Chronic Fatigue Syndr. 2003;11:71&#x2013;95. doi: 10.1300/J092v11n02_06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1300/J092v11n02_06</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr J.R., Petty R., Burke B., Gough J., Fear D., Sinclair L.I., Mattey D.L., Richards S.C., Montgomery J., Baldwin D.A., et al. Gene expression subtypes in patients with chronic fatigue syndrome/myalgic encephalomyelitis. J. Infect. Dis. 2008;197:1171&#x2013;1184. doi: 10.1086/533453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/533453</ArticleId><ArticleId IdType="pubmed">18462164</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoothoff J., Gleason K., McManimen S., Thorpe T., Jason L.A. Subtyping Patients with Myalgic Encephalomyelitis (ME) and Chronic Fatigue Syndrome (CFS) By Course of Illness. J. Biosens. Biomark. Diagn. 2017;2:1&#x2013;17. doi: 10.15226/2575-6303/2/1/00113.</Citation><ArticleIdList><ArticleId IdType="doi">10.15226/2575-6303/2/1/00113</ArticleId><ArticleId IdType="pmc">PMC5710812</ArticleId><ArticleId IdType="pubmed">29204592</ArticleId></ArticleIdList></Reference><Reference><Citation>Nacul L., O&#x2019;Boyle S., Palla L., Nacul F.E., Mudie K., Kingdon C.C., Cliff J.M., Clark T.G., Dockrell H.M., Lacerda E.M. How Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Progresses: The Natural History of ME/CFS. Front. Neurol. 2020;11:826. doi: 10.3389/fneur.2020.00826.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00826</ArticleId><ArticleId IdType="pmc">PMC7431524</ArticleId><ArticleId IdType="pubmed">32849252</ArticleId></ArticleIdList></Reference><Reference><Citation>Helliwell A.M., Stockwell P.A., Edgar C.D., Chatterjee A., Tate W.P. Dynamic Epigenetic Changes during a Relapse and Recovery Cycle in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Int. J. Mol. Sci. 2022;23:11852. doi: 10.3390/ijms231911852.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231911852</ArticleId><ArticleId IdType="pmc">PMC9570248</ArticleId><ArticleId IdType="pubmed">36233152</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomas C., Brown A., Strassheim V., Elson J.L., Newton J., Manning P. Cellular bioenergetics is impaired in patients with chronic fatigue syndrome. PLoS ONE. 2017;12:e0186802. doi: 10.1371/journal.pone.0186802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0186802</ArticleId><ArticleId IdType="pmc">PMC5655451</ArticleId><ArticleId IdType="pubmed">29065167</ArticleId></ArticleIdList></Reference><Reference><Citation>ANZMES  ANZMES Preliminary Survey Findings. 2021.  [(accessed on 22 January 2023)].  Available online:  https://anzmes.org.nz/anzmes-preliminary-survey-findings/</Citation></Reference><Reference><Citation>Johnson C. Study Suggests Long COVID is Becoming More like Chronic Fatigue Syndrome (ME/CFS). Health Rising Blog. 2021.  [(accessed on 22 January 2023)].  Available online:  https://www.healthrising.org/blog/2021/05/17/long-covid-symptoms-chronic-fatigue-syndrome/</Citation></Reference><Reference><Citation>Brurberg K.G., F&#xf8;nhus M.S., Larun L., Flottorp S., Malterud K. Case definitions for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): A systematic review. BMJ Open. 2014;4:e003973. doi: 10.1136/bmjopen-2013-003973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2013-003973</ArticleId><ArticleId IdType="pmc">PMC3918975</ArticleId><ArticleId IdType="pubmed">24508851</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda K., Straus S.E., Hickie I., Sharpe M.C., Dobbins J.G., Komaroff A. The chronic fatigue syndrome: A comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann. Intern. Med. 1994;121:953&#x2013;959. doi: 10.7326/0003-4819-121-12-199412150-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-121-12-199412150-00009</ArticleId><ArticleId IdType="pubmed">7978722</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal A.S., Bradley A.S., Bishop K.N., Kiani-Alikhan S., Ford B. Chronic fatigue syndrome, the immune system and viral infection. Brain Behav. Immun. 2012;26:24&#x2013;31. doi: 10.1016/j.bbi.2011.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2011.06.016</ArticleId><ArticleId IdType="pubmed">21756995</ArticleId></ArticleIdList></Reference><Reference><Citation>Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Board on the Health of Select Populations. Institute of Medicine . Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. National Academies Press (US); Washington, DC, USA: 2015. The National Academies Collection: Reports funded by National Institutes of Health.</Citation><ArticleIdList><ArticleId IdType="doi">10.17226/19012</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Esfandyarpour R., Kashi A., Nemat-Gorgani M., Wilhelmy J., Davis R.W. A nanoelectronics-blood-based diagnostic biomarker for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Proc. Natl. Acad. Sci. USA. 2019;116:10250&#x2013;10257. doi: 10.1073/pnas.1901274116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1901274116</ArticleId><ArticleId IdType="pmc">PMC6535016</ArticleId><ArticleId IdType="pubmed">31036648</ArticleId></ArticleIdList></Reference><Reference><Citation>Missailidis D., Annesley S.J., Allan C.Y., Sanislav O., Lidbury B.A., Lewis D.P., Fisher P.R. An Isolated Complex V Inefficiency and Dysregulated Mitochondrial Function in Immortalized Lymphocytes from ME/CFS Patients. Int. J. Mol. Sci. 2020;21:1074. doi: 10.3390/ijms21031074.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21031074</ArticleId><ArticleId IdType="pmc">PMC7036826</ArticleId><ArticleId IdType="pubmed">32041178</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeus M., Nijs J., McGregor N., Meeusen R., De Schutter G., Truijen S., Fr&#xe9;mont M., Van Hoof E., De Meirleir K. Unravelling intracellular immune dysfunctions in chronic fatigue syndrome: Interactions between protein kinase R activity, RNase L cleavage and elastase activity, and their clinical relevance. In Vivo. 2008;22:115&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">18396793</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweetman E., Noble A., Edgar C., Mackay A., Helliwell A., Vallings R., Ryan M., Tate W. Current Research Provides Insight into the Biological Basis and Diagnostic Potential for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Diagnostics. 2019;9:73. doi: 10.3390/diagnostics9030073.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics9030073</ArticleId><ArticleId IdType="pmc">PMC6787691</ArticleId><ArticleId IdType="pubmed">31295930</ArticleId></ArticleIdList></Reference><Reference><Citation>Vernon S.D., Funk S., Bateman L., Stoddard G.J., Hammer S., Sullivan K., Bell J., Abbaszadeh S., Lipkin W.I., Komaroff A.L. Orthostatic Challenge Causes Distinctive Symptomatic, Hemodynamic and Cognitive Responses in Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Front. Med. (Lausanne) 2022;9:917019. doi: 10.3389/fmed.2022.917019.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.917019</ArticleId><ArticleId IdType="pmc">PMC9285104</ArticleId><ArticleId IdType="pubmed">35847821</ArticleId></ArticleIdList></Reference><Reference><Citation>Sep&#xfa;lveda N., Carneiro J., Lacerda E., Nacul L. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome as a Hyper-Regulated Immune System Driven by an Interplay Between Regulatory T Cells and Chronic Human Herpesvirus Infections. Front. Immunol. 2019;10:2684. doi: 10.3389/fimmu.2019.02684.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02684</ArticleId><ArticleId IdType="pmc">PMC6883905</ArticleId><ArticleId IdType="pubmed">31824487</ArticleId></ArticleIdList></Reference><Reference><Citation>Netea M.G., Joosten L.A., Latz E., Mills K.H., Natoli G., Stunnenberg H.G., O&#x2019;Neill L.A., Xavier R.J. Trained immunity: A program of innate immune memory in health and disease. Science. 2016;352:aaf1098. doi: 10.1126/science.aaf1098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf1098</ArticleId><ArticleId IdType="pmc">PMC5087274</ArticleId><ArticleId IdType="pubmed">27102489</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweetman E., Ryan M., Edgar C., MacKay A., Vallings R., Tate W. Changes in the transcriptome of circulating immune cells of a New Zealand cohort with myalgic encephalomyelitis/chronic fatigue syndrome. Int. J. Immunopathol. Pharmacol. 2019;33:402. doi: 10.1177/2058738418820402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2058738418820402</ArticleId><ArticleId IdType="pmc">PMC6350121</ArticleId><ArticleId IdType="pubmed">30791746</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweetman E., Kleffmann T., Edgar C., de Lange M., Vallings R., Tate W. A SWATH-MS analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome peripheral blood mononuclear cell proteomes reveals mitochondrial dysfunction. J. Transl. Med. 2020;18:365. doi: 10.1186/s12967-020-02533-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02533-3</ArticleId><ArticleId IdType="pmc">PMC7512220</ArticleId><ArticleId IdType="pubmed">32972442</ArticleId></ArticleIdList></Reference><Reference><Citation>Helliwell A.M., Sweetman E.C., Stockwell P.A., Edgar C.D., Chatterjee A., Tate W.P. Changes in DNA methylation profiles of myalgic encephalomyelitis/chronic fatigue syndrome patients reflect systemic dysfunctions. Clin. Epigenet. 2020;12:167. doi: 10.1186/s13148-020-00960-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13148-020-00960-z</ArticleId><ArticleId IdType="pmc">PMC7641803</ArticleId><ArticleId IdType="pubmed">33148325</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakatomi Y., Mizuno K., Ishii A., Wada Y., Tanaka M., Tazawa S., Onoe K., Fukuda S., Kawabe J., Takahashi K., et al. Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An (1)(1)C-(R)-PK11195 PET Study. J. Nucl. Med. 2014;55:945&#x2013;950. doi: 10.2967/jnumed.113.131045.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.113.131045</ArticleId><ArticleId IdType="pubmed">24665088</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser D., Golla S.S.V., Verfaillie S.C.J., Coomans E.M., Rikken R.M., van de Giessen E.M., den Hollander M.E., Verveen A., Yaqub M., Barkhof F., et al. Long COVID is associated with extensive in-vivoneuroinflammation on [18F]DPA-714 PET. medRxiv. 2022 doi: 10.1101/2022.06.02.22275916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.06.02.22275916</ArticleId></ArticleIdList></Reference><Reference><Citation>Subhramanyam C.S., Wang C., Hu Q., Dheen S.T. Microglia-mediated neuroinflammation in neurodegenerative diseases. Semin. Cell Dev. Biol. 2019;94:112&#x2013;120. doi: 10.1016/j.semcdb.2019.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2019.05.004</ArticleId><ArticleId IdType="pubmed">31077796</ArticleId></ArticleIdList></Reference><Reference><Citation>VanElzakker M.B., Brumfield S.A., Lara Mejia P.S. Neuroinflammation and Cytokines in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Critical Review of Research Methods. Front. Neurol. 2018;9:1033. doi: 10.3389/fneur.2018.01033.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01033</ArticleId><ArticleId IdType="pmc">PMC6335565</ArticleId><ArticleId IdType="pubmed">30687207</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C., Lin J.C., Sheriff S., Maudsley A.A., Younger J.W. Evidence of widespread metabolite abnormalities in Myalgic encephalomyelitis/chronic fatigue syndrome: Assessment with whole-brain magnetic resonance spectroscopy. Brain Imaging Behav. 2020;14:562&#x2013;572. doi: 10.1007/s11682-018-0029-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11682-018-0029-4</ArticleId><ArticleId IdType="pmc">PMC6612467</ArticleId><ArticleId IdType="pubmed">30617782</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson T., Zhang L.X., Guo H., Nacul L., Song X. Brainstem Abnormalities in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Scoping Review and Evaluation of Magnetic Resonance Imaging Findings. Front. Neurol. 2021;12:769511. doi: 10.3389/fneur.2021.769511.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.769511</ArticleId><ArticleId IdType="pmc">PMC8718708</ArticleId><ArticleId IdType="pubmed">34975729</ArticleId></ArticleIdList></Reference><Reference><Citation>Quadt L., Critchley H.D., Garfinkel S.N. The neurobiology of interoception in health and disease. Ann. N. Y. Acad. Sci. 2018;1428:112&#x2013;128. doi: 10.1111/nyas.13915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.13915</ArticleId><ArticleId IdType="pubmed">29974959</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiner P., Harrer T., Scheibenbogen C., Lamer S., Schlosser A., Naviaux R.K., Prusty B.K. Human Herpesvirus-6 Reactivation, Mitochondrial Fragmentation, and the Coordination of Antiviral and Metabolic Phenotypes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Immunohorizons. 2020;4:201&#x2013;215. doi: 10.4049/immunohorizons.2000006.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/immunohorizons.2000006</ArticleId><ArticleId IdType="pubmed">32327453</ArticleId></ArticleIdList></Reference><Reference><Citation>Bested A.C., Saunders P.R., Logan A.C. Chronic fatigue syndrome: Neurological findings may be related to blood&#x2013;brain barrier permeability. Med. Hypotheses. 2001;57:231&#x2013;237. doi: 10.1054/mehy.2001.1306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1054/mehy.2001.1306</ArticleId><ArticleId IdType="pubmed">11461179</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracey K.J. The inflammatory reflex. Nature. 2002;420:853&#x2013;859. doi: 10.1038/nature01321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01321</ArticleId><ArticleId IdType="pubmed">12490958</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Song Y., Chen Z., Leng S.X. Connection between Systemic Inflammation and Neuroinflammation Underlies Neuroprotective Mechanism of Several Phytochemicals in Neurodegenerative Diseases. Oxid. Med. Cell. Longev. 2018;2018:1972714. doi: 10.1155/2018/1972714.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/1972714</ArticleId><ArticleId IdType="pmc">PMC6196798</ArticleId><ArticleId IdType="pubmed">30402203</ArticleId></ArticleIdList></Reference><Reference><Citation>Olofsson P.S., Rosas-Ballina M., Levine Y.A., Tracey K.J. Rethinking inflammation: Neural circuits in the regulation of immunity. Immunol. Rev. 2012;248:188&#x2013;204. doi: 10.1111/j.1600-065X.2012.01138.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2012.01138.x</ArticleId><ArticleId IdType="pmc">PMC4536565</ArticleId><ArticleId IdType="pubmed">22725962</ArticleId></ArticleIdList></Reference><Reference><Citation>Watkins L.R., Maier S.F. Implications of immune-to-brain communication for sickness and pain. Proc. Natl. Acad. Sci. USA. 1999;96:7710&#x2013;7713. doi: 10.1073/pnas.96.14.7710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.14.7710</ArticleId><ArticleId IdType="pmc">PMC33606</ArticleId><ArticleId IdType="pubmed">10393885</ArticleId></ArticleIdList></Reference><Reference><Citation>Haruwaka K., Ikegami A., Tachibana Y., Ohno N., Konishi H., Hashimoto A., Matsumoto M., Kato D., Ono R., Kiyama H., et al. Dual microglia effects on blood brain barrier permeability induced by systemic inflammation. Nat. Commun. 2019;10:5816. doi: 10.1038/s41467-019-13812-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-13812-z</ArticleId><ArticleId IdType="pmc">PMC6925219</ArticleId><ArticleId IdType="pubmed">31862977</ArticleId></ArticleIdList></Reference><Reference><Citation>Herman J.P., McKlveen J.M., Ghosal S., Kopp B., Wulsin A., Makinson R., Scheimann J., Myers B. Regulation of the Hypothalamic-Pituitary-Adrenocortical Stress Response. Compr. Physiol. 2016;6:603&#x2013;621. doi: 10.1002/cphy.c150015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cphy.c150015</ArticleId><ArticleId IdType="pmc">PMC4867107</ArticleId><ArticleId IdType="pubmed">27065163</ArticleId></ArticleIdList></Reference><Reference><Citation>Thau L., Gandhi J., Sharma S. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2022. Physiology, Cortisol.</Citation><ArticleIdList><ArticleId IdType="pubmed">30855827</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G., Anderson G., Maes M. Hypothalamic-Pituitary-Adrenal Hypofunction in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) as a Consequence of Activated Immune-Inflammatory and Oxidative and Nitrosative Pathways. Mol. Neurobiol. 2017;54:6806&#x2013;6819. doi: 10.1007/s12035-016-0170-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0170-2</ArticleId><ArticleId IdType="pubmed">27766535</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannibal K.E., Bishop M.D. Chronic stress, cortisol dysfunction, and pain: A psychoneuroendocrine rationale for stress management in pain rehabilitation. Phys. Ther. 2014;94:1816&#x2013;1825. doi: 10.2522/ptj.20130597.</Citation><ArticleIdList><ArticleId IdType="doi">10.2522/ptj.20130597</ArticleId><ArticleId IdType="pmc">PMC4263906</ArticleId><ArticleId IdType="pubmed">25035267</ArticleId></ArticleIdList></Reference><Reference><Citation>Straub R.H., Cutolo M. Glucocorticoids and chronic inflammation. Rheumatology (Oxford) 2016;55:ii6&#x2013;ii14. doi: 10.1093/rheumatology/kew348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew348</ArticleId><ArticleId IdType="pubmed">27856655</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira G., Gillies H., Chanda S., Corbett M., Vernon S.D., Milani T., Bateman L. Acute Corticotropin-Releasing Factor Receptor Type 2 Agonism Results in Sustained Symptom Improvement in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Front. Syst. Neurosci. 2021;15:698240. doi: 10.3389/fnsys.2021.698240.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnsys.2021.698240</ArticleId><ArticleId IdType="pmc">PMC8441022</ArticleId><ArticleId IdType="pubmed">34539356</ArticleId></ArticleIdList></Reference><Reference><Citation>Segura-Aguilar J., Huenchuguala S. Aminochrome Induces Irreversible Mitochondrial Dysfunction by Inducing Autophagy Dysfunction in Parkinson&#x2019;s Disease. Front. Neurosci. 2018;12:106. doi: 10.3389/fnins.2018.00106.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00106</ArticleId><ArticleId IdType="pmc">PMC5859232</ArticleId><ArticleId IdType="pubmed">29593482</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinan T.G. Serotonin and the regulation of hypothalamic-pituitary-adrenal axis function. Life Sci. 1996;58:1683&#x2013;1694. doi: 10.1016/0024-3205(96)00066-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0024-3205(96)00066-5</ArticleId><ArticleId IdType="pubmed">8637392</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronaldson P.T., Davis T.P. Regulation of blood-brain barrier integrity by microglia in health and disease: A therapeutic opportunity. J. Cereb. Blood Flow Metab. 2020;40:S6&#x2013;S24. doi: 10.1177/0271678X20951995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0271678X20951995</ArticleId><ArticleId IdType="pmc">PMC7687032</ArticleId><ArticleId IdType="pubmed">32928017</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariza M.E. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Human Herpesviruses Are Back! Biomolecules. 2021;11:185. doi: 10.3390/biom11020185.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11020185</ArticleId><ArticleId IdType="pmc">PMC7912523</ArticleId><ArticleId IdType="pubmed">33572802</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams M.V., Cox B., Lafuse W.P., Ariza M.E. Epstein-Barr Virus dUTPase Induces Neuroinflammatory Mediators: Implications for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Clin. Ther. 2019;41:848&#x2013;863. doi: 10.1016/j.clinthera.2019.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2019.04.009</ArticleId><ArticleId IdType="pmc">PMC6525645</ArticleId><ArticleId IdType="pubmed">31040055</ArticleId></ArticleIdList></Reference><Reference><Citation>A&#xef;d S., Bosetti F. Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications. Biochimie. 2011;93:46&#x2013;51. doi: 10.1016/j.biochi.2010.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2010.09.009</ArticleId><ArticleId IdType="pmc">PMC3008299</ArticleId><ArticleId IdType="pubmed">20868723</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasimir F., Toomey D., Liu Z., Kaiping A.C., Ariza M.E., Prusty B.K. Tissue specific signature of HHV-6 infection in ME/CFS. Front. Mol. Biosci. 2022;9:1044964. doi: 10.3389/fmolb.2022.1044964.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2022.1044964</ArticleId><ArticleId IdType="pmc">PMC9795011</ArticleId><ArticleId IdType="pubmed">36589231</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillman E.T., Lu H., Yao T., Nakatsu C.H. Microbial Ecology along the Gastrointestinal Tract. Microbes Environ. 2017;32:300&#x2013;313. doi: 10.1264/jsme2.ME17017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1264/jsme2.ME17017</ArticleId><ArticleId IdType="pmc">PMC5745014</ArticleId><ArticleId IdType="pubmed">29129876</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou K., Wu Z.X., Chen X.Y., Wang J.Q., Zhang D., Xiao C., Zhu D., Koya J.B., Wei L., Li J., et al. Microbiota in health and diseases. Signal Transduct. Target. Ther. 2022;7:135. doi: 10.1038/s41392-022-00974-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00974-4</ArticleId><ArticleId IdType="pmc">PMC9034083</ArticleId><ArticleId IdType="pubmed">35461318</ArticleId></ArticleIdList></Reference><Reference><Citation>Carding S., Verbeke K., Vipond D.T., Corfe B.M., Owen L.J. Dysbiosis of the gut microbiota in disease. Microb. Ecol. Health Dis. 2015;26:26191. doi: 10.3402/mehd.v26.26191.</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/mehd.v26.26191</ArticleId><ArticleId IdType="pmc">PMC4315779</ArticleId><ArticleId IdType="pubmed">25651997</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H., Liu M., Cao J., Li X., Fan D., Xia Y., Lu X., Li J., Ju D., Zhao H. The Dynamic Interplay between the Gut Microbiota and Autoimmune Diseases. J. Immunol. Res. 2019;2019:7546047. doi: 10.1155/2019/7546047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/7546047</ArticleId><ArticleId IdType="pmc">PMC6854958</ArticleId><ArticleId IdType="pubmed">31772949</ArticleId></ArticleIdList></Reference><Reference><Citation>Giloteaux L., Goodrich J.K., Walters W.A., Levine S.M., Ley R.E., Hanson M.R. Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome. 2016;4:30. doi: 10.1186/s40168-016-0171-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40168-016-0171-4</ArticleId><ArticleId IdType="pmc">PMC4918027</ArticleId><ArticleId IdType="pubmed">27338587</ArticleId></ArticleIdList></Reference><Reference><Citation>Newberry F., Hsieh S.Y., Wileman T., Carding S.R. Does the microbiome and virome contribute to myalgic encephalomyelitis/chronic fatigue syndrome? Clin. Sci. (Lond.) 2018;132:523&#x2013;542. doi: 10.1042/CS20171330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20171330</ArticleId><ArticleId IdType="pmc">PMC5843715</ArticleId><ArticleId IdType="pubmed">29523751</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallis A., Ball M., Butt H., Lewis D.P., McKechnie S., Paull P., Jaa-Kwee A., Bruck D. Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: Neuropsychological symptoms and sex comparisons. J. Transl. Med. 2018;16:24. doi: 10.1186/s12967-018-1392-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-018-1392-z</ArticleId><ArticleId IdType="pmc">PMC5801817</ArticleId><ArticleId IdType="pubmed">29409505</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao A.V., Bested A.C., Beaulne T.M., Katzman M.A., Iorio C., Berardi J.M., Logan A.C. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog. 2009;1:6. doi: 10.1186/1757-4749-1-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1757-4749-1-6</ArticleId><ArticleId IdType="pmc">PMC2664325</ArticleId><ArticleId IdType="pubmed">19338686</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan A., Nord C.E., Eveng&#xe5;rd B. Effect of supplement with lactic-acid producing bacteria on fatigue and physical activity in patients with chronic fatigue syndrome. Nutr. J. 2009;8:4. doi: 10.1186/1475-2891-8-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1475-2891-8-4</ArticleId><ArticleId IdType="pmc">PMC2642862</ArticleId><ArticleId IdType="pubmed">19171024</ArticleId></ArticleIdList></Reference><Reference><Citation>Borody T.J., Nowak A., Finlayson S. The GI microbiome and its role in Chronic Fatigue Syndrome: A summary of bacteriotherapy. J. Australas. Coll. Nutr. Environ. Med. 2012;31:3&#x2013;8.</Citation></Reference><Reference><Citation>Guo C., Che X., Briese T., Ranjan A., Allicock O., Yates R.A., Cheng A., March D., Hornig M., Komaroff A.L., et al. Deficient butyrate-producing capacity in the gut microbiome is associated with bacterial network disturbances and fatigue symptoms in ME/CFS. Cell Host Microbe. 2023;31:288&#x2013;304. doi: 10.1016/j.chom.2023.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2023.01.004</ArticleId><ArticleId IdType="pmc">PMC10183837</ArticleId><ArticleId IdType="pubmed">36758522</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong R., Gunter C., Fleming E., Vernon S.D., Bateman L., Unutmaz D., Oh J. Multi-&#x2019;omics of gut microbiome-host interactions in short- and long-term myalgic encephalomyelitis/chronic fatigue syndrome patients. Cell Host Microbe. 2023;31:273&#x2013;287. doi: 10.1016/j.chom.2023.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2023.01.001</ArticleId><ArticleId IdType="pmc">PMC10353054</ArticleId><ArticleId IdType="pubmed">36758521</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson M.R., Giloteaux L. The gut microbiome in Myalgic Encephalomyelitis. Biochemist. 2017;39:10&#x2013;13. doi: 10.1042/BIO03902010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BIO03902010</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai Y.L., Lin T.L., Chang C.J., Wu T.R., Lai W.F., Lu C.C., Lai H.C. Probiotics, prebiotics and amelioration of diseases. J. Biomed. Sci. 2019;26:3. doi: 10.1186/s12929-018-0493-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-018-0493-6</ArticleId><ArticleId IdType="pmc">PMC6320572</ArticleId><ArticleId IdType="pubmed">30609922</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukla S.K., Cook D., Meyer J., Vernon S.D., Le T., Clevidence D., Robertson C.E., Schrodi S.J., Yale S., Frank D.N. Changes in Gut and Plasma Microbiome following Exercise Challenge in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) PLoS ONE. 2015;10:e0145453. doi: 10.1371/journal.pone.0145453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0145453</ArticleId><ArticleId IdType="pmc">PMC4684203</ArticleId><ArticleId IdType="pubmed">26683192</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes M., Kubera M., Leunis J.C., Berk M. Increased IgA and IgM responses against gut commensals in chronic depression: Further evidence for increased bacterial translocation or leaky gut. J. Affect. Disord. 2012;141:55&#x2013;62. doi: 10.1016/j.jad.2012.02.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2012.02.023</ArticleId><ArticleId IdType="pubmed">22410503</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheedy J.R., Wettenhall R.E., Scanlon D., Gooley P.R., Lewis D.P., McGregor N., Stapleton D.I., Butt H.L., KL D.E.M. Increased d-lactic Acid intestinal bacteria in patients with chronic fatigue syndrome. In Vivo. 2009;23:621&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pubmed">19567398</ArticleId></ArticleIdList></Reference><Reference><Citation>Bested A.C., Logan A.C., Selhub E.M. Intestinal microbiota, probiotics and mental health: From Metchnikoff to modern advances: Part I&#x2014;Autointoxication revisited. Gut Pathog. 2013;5:5. doi: 10.1186/1757-4749-5-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1757-4749-5-5</ArticleId><ArticleId IdType="pmc">PMC3607857</ArticleId><ArticleId IdType="pubmed">23506618</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenyon J.N., Coe S., Izadi H. A retrospective outcome study of 42 patients with Chronic Fatigue Syndrome, 30 of whom had Irritable Bowel Syndrome. Half were treated with oral approaches, and half were treated with Faecal Microbiome Transplantation. Hum. Microbiome J. 2019;13:100061. doi: 10.1016/j.humic.2019.100061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humic.2019.100061</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;nig R.S., Albrich W.C., Kahlert C.R., Bahr L.S., L&#xf6;ber U., Vernazza P., Scheibenbogen C., Forslund S.K. The Gut Microbiome in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) Front. Immunol. 2021;12:628741. doi: 10.3389/fimmu.2021.628741.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.628741</ArticleId><ArticleId IdType="pmc">PMC8761622</ArticleId><ArticleId IdType="pubmed">35046929</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro-Marrero J., Domingo J.C., Cordobilla B., Ferrer R., Giralt M., Sanmart&#xed;n-Senta&#xf1;es R., Alegre-Mart&#xed;n J. Does Coenzyme Q10 Plus Selenium Supplementation Ameliorate Clinical Outcomes by Modulating Oxidative Stress and Inflammation in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome? Antioxid. Redox Signal. 2022;36:729&#x2013;739. doi: 10.1089/ars.2022.0018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2022.0018</ArticleId><ArticleId IdType="pmc">PMC9057907</ArticleId><ArticleId IdType="pubmed">35229657</ArticleId></ArticleIdList></Reference><Reference><Citation>Barletta M.A., Marino G., Spagnolo B., Bianchi F.P., Falappone P.C.F., Spagnolo L., Gatti P. Coenzyme Q10 + alpha lipoic acid for chronic COVID syndrome. Clin. Exp. Med. 2022;22:1&#x2013;12. doi: 10.1007/s10238-022-00871-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-022-00871-8</ArticleId><ArticleId IdType="pmc">PMC9395797</ArticleId><ArticleId IdType="pubmed">35994177</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes I.B., Gravallese E.M. Immune-mediated inflammatory disease therapeutics: Past, present and future. Nat. Rev. Immunol. 2021;21:680&#x2013;686. doi: 10.1038/s41577-021-00603-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00603-1</ArticleId><ArticleId IdType="pmc">PMC8436867</ArticleId><ArticleId IdType="pubmed">34518662</ArticleId></ArticleIdList></Reference><Reference><Citation>Fluge &#xd8;., Bruland O., Risa K., Storstein A., Kristoffersen E.K., Sapkota D., N&#xe6;ss H., Dahl O., Nyland H., Mella O. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLoS ONE. 2011;6:e26358. doi: 10.1371/journal.pone.0026358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0026358</ArticleId><ArticleId IdType="pmc">PMC3198463</ArticleId><ArticleId IdType="pubmed">22039471</ArticleId></ArticleIdList></Reference><Reference><Citation>Fluge &#xd8;., Risa K., Lunde S., Alme K., Rekeland I.G., Sapkota D., Kristoffersen E.K., S&#xf8;rland K., Bruland O., Dahl O., et al. B-Lymphocyte Depletion in Myalgic Encephalopathy/Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment. PLoS ONE. 2015;10:e0129898. doi: 10.1371/journal.pone.0129898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0129898</ArticleId><ArticleId IdType="pmc">PMC4488509</ArticleId><ArticleId IdType="pubmed">26132314</ArticleId></ArticleIdList></Reference><Reference><Citation>Fluge &#xd8;., Rekeland I.G., Lien K., Th&#xfc;rmer H., Borchgrevink P.C., Sch&#xe4;fer C., S&#xf8;rland K., A&#xdf;mus J., Ktoridou-Valen I., Herder I., et al. B-Lymphocyte Depletion in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Ann. Intern. Med. 2019;170:585&#x2013;593. doi: 10.7326/M18-1451.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M18-1451</ArticleId><ArticleId IdType="pubmed">30934066</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolton M.J., Chapman B.P., Van Marwijk H. Low-dose naltrexone as a treatment for chronic fatigue syndrome. BMJ Case Rep. 2020;13:e232502. doi: 10.1136/bcr-2019-232502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2019-232502</ArticleId><ArticleId IdType="pmc">PMC6954765</ArticleId><ArticleId IdType="pubmed">31911410</ArticleId></ArticleIdList></Reference><Reference><Citation>Polo O., Pesonen P., Tuominen E. Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Fatigue Biomed. Health Behav. 2019;7:207&#x2013;217. doi: 10.1080/21641846.2019.1692770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21641846.2019.1692770</ArticleId></ArticleIdList></Reference><Reference><Citation>Eaton-Fitch N., Du Preez S., Cabanas H., Muraki K., Staines D., Marshall-Gradisnik S. Impaired TRPM3-dependent calcium influx and restoration using Naltrexone in natural killer cells of myalgic encephalomyelitis/chronic fatigue syndrome patients. J. Transl. Med. 2022;20:94. doi: 10.1186/s12967-022-03297-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03297-8</ArticleId><ArticleId IdType="pmc">PMC8848670</ArticleId><ArticleId IdType="pubmed">35172836</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpi-Abadie J., Kaye A.M., Kaye A.D. Serotonin syndrome. Ochsner J. 2013;13:533&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3865832</ArticleId><ArticleId IdType="pubmed">24358002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashi A.A., Davis R.W., Phair R.D. The IDO Metabolic Trap Hypothesis for the Etiology of ME/CFS. Diagnostics. 2019;9:82. doi: 10.3390/diagnostics9030082.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics9030082</ArticleId><ArticleId IdType="pmc">PMC6787624</ArticleId><ArticleId IdType="pubmed">31357483</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul B.D., Lemle M.D., Komaroff A.L., Snyder S.H. Redox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome. Proc. Natl. Acad. Sci. USA. 2021;118:2024358118. doi: 10.1073/pnas.2024358118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2024358118</ArticleId><ArticleId IdType="pmc">PMC8403932</ArticleId><ArticleId IdType="pubmed">34400495</ArticleId></ArticleIdList></Reference><Reference><Citation>Gueven N., Ravishankar P., Eri R., Rybalka E. Idebenone: When an antioxidant is not an antioxidant. Redox Biol. 2021;38:101812. doi: 10.1016/j.redox.2020.101812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2020.101812</ArticleId><ArticleId IdType="pmc">PMC7708875</ArticleId><ArticleId IdType="pubmed">33254077</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebedeva A.V., Shchukin I.A., Soldatov M.A., Bo&#x12d;ko O.V., Petrov S.V., Khozova A.A., Ismailov A.M., Shikhkerimov R.K., Bo&#x12d;ko A.N. [Asthenia, emotional disorders and quality of life of patients with multiple sclerosis] Zhurnal Nevrol. I Psikhiatrii Im. SS Korsakova. 2014;114:99&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">25591540</ArticleId></ArticleIdList></Reference><Reference><Citation>Tereshin A.E., Kiryanova V.V., Reshetnik D.A. Correction of Mitochondrial Dysfunction in the Complex Rehabilitation of COVID-19 Patients. Neurosci. Behav. Physiol. 2022;52:511&#x2013;514. doi: 10.1007/s11055-022-01269-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11055-022-01269-5</ArticleId><ArticleId IdType="pmc">PMC9304544</ArticleId><ArticleId IdType="pubmed">35892008</ArticleId></ArticleIdList></Reference><Reference><Citation>Montes Diaz G., Hupperts R., Fraussen J., Somers V. Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies. Autoimmun. Rev. 2018;17:1240&#x2013;1250. doi: 10.1016/j.autrev.2018.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2018.07.001</ArticleId><ArticleId IdType="pubmed">30316988</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson M.F., Nilsson M., Eriksson P.S., Sims N.R. Glutathione monoethyl ester provides neuroprotection in a rat model of stroke. Neurosci. Lett. 2004;354:163&#x2013;165. doi: 10.1016/j.neulet.2003.09.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2003.09.067</ArticleId><ArticleId IdType="pubmed">14698463</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Sapper T.N., Mah E., Rudraiah S., Schill K.E., Chitchumroonchokchai C., Moller M.V., McDonald J.D., Rohrer P.R., Manautou J.E., et al. Green tea extract provides extensive Nrf2-independent protection against lipid accumulation and NF&#x3ba;B pro- inflammatory responses during nonalcoholic steatohepatitis in mice fed a high-fat diet. Mol. Nutr. Food Res. 2016;60:858&#x2013;870. doi: 10.1002/mnfr.201500814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mnfr.201500814</ArticleId><ArticleId IdType="pmc">PMC4828297</ArticleId><ArticleId IdType="pubmed">26679056</ArticleId></ArticleIdList></Reference><Reference><Citation>Frei B., England L., Ames B.N. Ascorbate is an outstanding antioxidant in human blood plasma. Proc. Natl. Acad. Sci. USA. 1989;86:6377&#x2013;6381. doi: 10.1073/pnas.86.16.6377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.86.16.6377</ArticleId><ArticleId IdType="pmc">PMC297842</ArticleId><ArticleId IdType="pubmed">2762330</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruno R.S., Leonard S.W., Atkinson J., Montine T.J., Ramakrishnan R., Bray T.M., Traber M.G. Faster plasma vitamin E disappearance in smokers is normalized by vitamin C supplementation. Free Radic. Biol. Med. 2006;40:689&#x2013;697. doi: 10.1016/j.freeradbiomed.2005.10.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2005.10.051</ArticleId><ArticleId IdType="pubmed">16458200</ArticleId></ArticleIdList></Reference><Reference><Citation>Dysken M.W., Sano M., Asthana S., Vertrees J.E., Pallaki M., Llorente M., Love S., Schellenberg G.D., McCarten J.R., Malphurs J., et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial. JAMA. 2014;311:33&#x2013;44. doi: 10.1001/jama.2013.282834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.282834</ArticleId><ArticleId IdType="pmc">PMC4109898</ArticleId><ArticleId IdType="pubmed">24381967</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayin V.I., Ibrahim M.X., Larsson E., Nilsson J.A., Lindahl P., Bergo M.O. Antioxidants accelerate lung cancer progression in mice. Sci. Transl. Med. 2014;6:215&#x2013;221. doi: 10.1126/scitranslmed.3007653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007653</ArticleId><ArticleId IdType="pubmed">24477002</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretz D., Heyward P.M., Krebs J., Gruchot J., Barter C., Silcock P., Downes N., Rizwan M.Z., Boucsein A., Bender J., et al. A dahlia flower extract improves glucose homeostasis by improving insulin function in the brain. Medxiv. 2023 in submission .</Citation></Reference><Reference><Citation>White P.D., Goldsmith K.A., Johnson A.L., Potts L., Walwyn R., DeCesare J.C., Baber H.L., Burgess M., Clark L.V., Cox D.L., et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): A randomised trial. Lancet. 2011;377:823&#x2013;836. doi: 10.1016/S0140-6736(11)60096-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(11)60096-2</ArticleId><ArticleId IdType="pmc">PMC3065633</ArticleId><ArticleId IdType="pubmed">21334061</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharpe M., Goldsmith K.A., Johnson A.L., Chalder T., Walker J., White P.D. Rehabilitative treatments for chronic fatigue syndrome: Long-term follow-up from the PACE trial. Lancet Psychiatry. 2015;2:1067&#x2013;1074. doi: 10.1016/S2215-0366(15)00317-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(15)00317-X</ArticleId><ArticleId IdType="pubmed">26521770</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE  Myalgic Encephalomyelitis (or Encephalopathy)/Chronic Fatigue Syndrome: Diagnosis and Management.  [(accessed on 22 January 2023)].  Available online:  https://www.nice.org.uk/guidance/ng206.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>ANZMES  Lightning Process.  [(accessed on 22 January 2023)].  Available online:  https://anzmes.org.nz/lightning-process-switch/</Citation></Reference><Reference><Citation>Hopper A. Wired for Healing. Friesens; Altona, MB, Canada: 2014.</Citation></Reference><Reference><Citation>Reesor C. A Nurse with ME/CFS Finds Help in a Surprising Place: Christine&#x2019;s DNRS Recovery Story. 2020.  [(accessed on 22 January 2022)].  Available online:  https://www.healthrising.org/blog/2020/01/05/christines-dnrs-chronic-fatigue-recovery-story/</Citation></Reference><Reference><Citation>Bateman L., Bested A.C., Bonilla H.F., Chheda B.V., Chu L., Curtin J.M., Dempsey T.T., Dimmock M.E., Dowell T.G., Felsenstein D., et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management. Mayo Clin. Proc. 2021;96:2861&#x2013;2878. doi: 10.1016/j.mayocp.2021.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2021.07.004</ArticleId><ArticleId IdType="pubmed">34454716</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>